Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation

Atherosclerosis

Volumn 225, Issue 1, 2012, Pages 166-172

  Schirmer, Stephan H ^a   Werner, Christian M ^a   Binder, Stephan B G ^a   Faas, Maria E ^a   Custodis, Florian ^a   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Monocytes; Polyunsaturated fatty acids; Postprandial; Triglycerides

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; FRACTALKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 ACID ETHYL ESTER; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FAT INTAKE; FAT TOLERANCE TEST; FEMALE; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MALE; MONOCYTE; MONOCYTOPENIA; NEUTROPHILIA; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CHEMOKINE CCL2; CHEMOKINE CX3CL1; CHOLESTEROL; CORONARY ARTERY DISEASE; DIETARY FATS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MONOCYTES; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 84867855902     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.09.002     Document Type: Article

References (34)

1. Goldberg I.J., Eckel R.H., McPherson R. Triglycerides and heart disease. Arterioscler Thromb Vasc Biol 2011, 31:1716-1725.
2. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
3. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361.
4. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation 1979, 60:473-485.
5. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. J Am Med Assoc 2007, 298:309-316.
6. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. J Am Med Assoc 2007, 298:299-308.
7. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508.
8. Schirmer S.H., Fledderus J.O., van der Laan A.M., et al. Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol 2009, 46:177-185.
9. Alipour A., van Oostrom A.J.H.H.M., Izraeljan A., et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008, 28:792-797.
10. Gower R.M., Wu H., Foster G.A., et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011, 31:160-166.
11. van Oostrom A.J., Rabelink T.J., Verseyden C., et al. Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis 2004, 177:175-182.
12. Balk E.M., Lichtenstein A.H., Chung M., Kupelnick B., Chew P., Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19-30.
13. Lee J.Y., Plakidas A., Lee W.H., et al. Differential modulation of toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 2003, 44:479-486.
14. Schirmer S.H., Fledderus J.O., Bot P.T., et al. Interferon-beta signaling is enhanced in patients with insufficient coronary collateral artery development and inhibits arteriogenesis in mice. Circ Res 2008, 102:1286-1294.
15. Azab B., Zaher M., Weiserbs K.F., et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol 2010, 106:470-476.
16. Morrow J.D., Frei B., Longmire A.W., et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995, 332:1198-1203.
17. Zilversmit D.B. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins. Circ Res 1973, 33:633-638.
18. Chung B.H., Segrest J.P., Smith K., Griffin F.M., Brouillette C.G. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis?. J Clin Invest 1989, 83:1363-1374.
19. Petrovsky N., McNair P., Harrison L.C. Diurnal rhythms of pro-inflammatory cytokines: regulation by plasma cortisol and therapeutic implications. Cytokine 1998, 10:307-312.
20. Sampson M.J., Davies I.R., Brown J.C., Ivory K., Hughes D.A. Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients. Arterioscler Thromb Vasc Biol 2002, 22:1187-1193.
21. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455.
22. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
23. Rauch B., Schiele R., Schneider S., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122:2152-2159.
24. De Caterina R. n-3 fatty acids in cardiovascular disease. N Engl J Med 2011, 364:2439-2450.
25. Park Y., Harris W.S. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003, 44:455-463.
26. Harris W.S., Connor W.E., Alam N., Illingworth D.R. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res 1988, 29:1451-1460.
27. Zhang W.Y., Schwartz E., Wang Y., Attrep J., Li Z., Reaven P. Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26:514-519.
28. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stampfer M.J., Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.
29. Carrepeiro M.M., Rogero M.M., Bertolami M.C., Botelho P.B., Castro N., Castro I.A. Effect of n-3 fatty acids and statins on oxidative stress in statin-treated hypercholestorelemic and normocholesterolemic women. Atherosclerosis 2011, 217:171-178.
30. Rumley A.G., Woodward M., Rumley A., Rumley J., Lowe G.D.O. Plasma lipid peroxides: relationships to cardiovascular risk factors and prevalent cardiovascular disease. QJM 2004, 97:809-816.
31. Tuomisto T.T., Lumivuori H., Kansanen E., et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc Res 2008, 78:175-184.
32. Griffin M.D., Sanders T.A., Davies I.G., et al. Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45-70 y: the OPTILIP study. Am J Clin Nutr 2006, 84:1290-1298.
33. Tinker L.F., Parks E.J., Behr S.R., Schneeman B.O., Davis P.A. (n-3) fatty acid supplementation in moderately hypertriglyceridemic adults changes postprandial lipid and apolipoprotein B responses to a standardized test meal. J Nutr 1999, 129:1126-1134.
34. Westphal S., Orth M., Ambrosch A., Osmundsen K., Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr 2000, 71:914-920.